Novartis will incur a charge of nearly $600 million after it halted development of investigational drugs for hepatitis C and …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility

